Traws Pharma, Inc. (TRAW)

NASDAQ: TRAW · Real-Time Price · USD
1.400
-0.010 (-0.71%)
May 8, 2025, 4:00 PM EDT - Market closed
-0.71%
Market Cap 7.10M
Revenue (ttm) 226,000
Net Income (ttm) -54.67M
Shares Out 5.07M
EPS (ttm) -35.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 230,339
Open 1.440
Previous Close 1.410
Day's Range 1.320 - 1.525
52-Week Range 1.320 - 19.440
Beta 1.59
Analysts n/a
Price Target n/a
Earnings Date May 19, 2025

About TRAW

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID-19; and TRX100 (Tivoxavir marboxil), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kina... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 25, 2013
Employees 7
Stock Exchange NASDAQ
Ticker Symbol TRAW
Full Company Profile

Financial Performance

In 2024, Traws Pharma's revenue was $226,000, a change of 0.00% compared to the previous year's $226,000. Losses were -$54.67 million, 188.5% more than in 2023.

Financial numbers in USD Financial Statements

News

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Traws Pharma, Inc. (NASDAQ:TRAW) Virtual Investor Event March 31, 2025 10:00 AM ET Company Participants Werner Cautreels – Chief Executive Officer Robert Redfield – Chief Medical Officer David Pauza ...

5 weeks ago - Seeking Alpha

Traws Pharma Announces Management Updates

NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to ...

5 weeks ago - GlobeNewsWire

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Event to highlight the differentiated features of Traws oral small molecule product candidates: Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease inhibitor for Bird Flu Ratutrelvir, a main...

6 weeks ago - GlobeNewsWire

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

NEWTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to ...

6 weeks ago - GlobeNewsWire

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

NEWTOWN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to ...

6 weeks ago - GlobeNewsWire

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

NEWTOWN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule...

2 months ago - GlobeNewsWire

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

NEWTOWN, Pa., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW) (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for the treatm...

2 months ago - GlobeNewsWire

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Phase I completed in healthy volunteers with pharmacokinetic data supporting dosing for both therapeutic and further development for bird flu prevention NEWTOWN, Pa. , Jan. 23, 2025 /PRNewswire/ -- Tr...

3 months ago - PRNewsWire

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

SAN DIEGO , Jan. 10, 2025 /PRNewswire/ -- Expert Systems, a hybrid AI enabled drug discovery and development accelerator, announced a significant milestone in a development of Traws Pharma, Inc. 's (N...

4 months ago - PRNewsWire

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Initial tranche of $20 Million extends cash runway into 1H26, subsequent tranche of up to $52.6 Million will provide for runway 3+ years enabling the company to reach both near-term and long-term valu...

4 months ago - PRNewsWire

Traws Pharma stock soars 200% on encouraging bird flu drug data

Shares of Traws Pharma Inc (NASDAQ: TRAW) more than tripled today after reporting encouraging early-stage data for its tivoxavir marboxil as a treatment of H5N1 bird flu. The investigational drug demo...

4 months ago - Invezz

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Investigational agent in development for treatment or prevention of H5N1 Bird Flu Phase 1 dosing completed in healthy volunteers   Potent inhibition of drug-resistant and bird flu viruses in vitro In ...

4 months ago - PRNewsWire

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

NEWTOWN, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral disease...

6 months ago - GlobeNewsWire

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy volunteers demonstrated positive tolerability res...

7 months ago - GlobeNewsWire

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir

7 months ago - GlobeNewsWire

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws' Further Transformation and Growth

8 months ago - GlobeNewsWire

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws' shares expected to begin trading on a split-adjust...

8 months ago - GlobeNewsWire

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Traws Pharma, Inc. (NASDAQ:TRAW) Corporate Update Call August 15, 2024 8:00 AM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Werner Cautreels - CEO Mark Guerin - CFO Conference Call Par...

9 months ago - Seeking Alpha

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical ...

9 months ago - GlobeNewsWire

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral disease...

9 months ago - GlobeNewsWire

Traws Pharma Announces New Employee Inducement Grants

NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection ...

1 year ago - GlobeNewsWire

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

NEWTOWN, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and develo...

1 year ago - GlobeNewsWire

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compa...

1 year ago - GlobeNewsWire

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developin...

1 year ago - GlobeNewsWire

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Steve Fruchtman - President and CEO Vi...

1 year ago - Seeking Alpha